Tumor initiation in human malignant melanoma and potential cancer therapies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 131-136

  Ma, Jie ^a   Frank, Markus H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ABCB5; Angiogenesis; Cancer stem cells; Immunity; Malignant melanoma initiating cells; Melanoma; Melanoma stem cells

Indexed keywords

ABC TRANSPORTER; ABCB5; CD133 ANTIGEN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CELL RENEWAL; DISEASE COURSE; ENDOTHELIUM CELL; HOST RESISTANCE; IMMUNOMODULATION; MELANOMA; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SCID MOUSE; STEM CELL TRANSPLANTATION; TISSUE MICROARRAY; TUMOR IMMUNITY; XENOTRANSPLANTATION;

EID: 77950829074     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010790909254     Document Type: Review

References (46)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics 2008. CA Cancer J. Clin., 2008, 58(2), 71-96.
2. Cummins, D.L.; Cummins, J.M.; Pantle, H.; Silverman, M.A.; Leonard, A.L.; Chanmugam, A. Cutaneous malignant melanoma. Mayo Clin. Proc., 2006, 81(4), 500-507.
3. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859), 105-111.
4. Frank, N.Y.; Schatton, T.; Frank, M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest., 2010, 120(1), 41-50.
5. Schatton, T.; Frank, N.Y.; Frank, M.H. Identification and targeting of cancer stem cells. Bioessays, 2009, 31(10), 1038-1049.
6. Schatton, T.; Murphy, G.F.; Frank, N.Y.; Yamaura, K.; Waaga-Gasser, A.M.; Gasser, M.; Zhan, Q.; Jordan, S.; Duncan, L.M.; Weishaupt, C.; Fuhlbrigge, R.C.; Kupper, T.S.; Sayegh, M.H.; Frank, M.H. Identification of cells initiating human melanomas. Nature, 2008, 451(7176), 345-349.
7. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res., 2006, 66(19), 9339-9344.
8. Fang, D.; Nguyen, T.K.; Leishear, K.; Finko, R.; Kulp, A.N.; Hotz, S.; Van Belle, P.A.; Xu, X.; Elder, D.E.; Herlyn, M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res., 2005, 65(20), 9328-9337.
9. Grichnik, J.M.; Burch, J.A.; Schulteis, R.D.; Shan, S.; Liu, J.; Darrow, T.L.; Vervaert, C.E.; Seigler, H.F. Melanoma, a tumor based on a mutant stem cell? J. Invest. Dermatol., 2006, 126(1), 142-153.
10. Goodell, M.A.; Brose, K.; Paradis, G.; Conner, A.S.; Mulligan, R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med., 1996, 183(4), 1797-1806.
11. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
12. Frank, N.Y.; Pendse, S.S.; Lapchak, P.H.; Margaryan, A.; Shlain, D.; Doeing, C.; Sayegh, M.H.; Frank, M.H. Multidrug resistance in cancer: role of ATP-dependent transporters. J. Biol. Chem., 2003, 278(47), 47156-47165.
13. Frank, N.Y.; Margaryan, A.; Huang, Y.; Schatton, T.; Waaga-Gasser, A.M.; Gasser, M.; Sayegh, M.H.; Sadee, W.; Frank, M.H. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res., 2005, 65(10), 4320-4333.
14. Klein, W.M.; Wu, B.P.; Zhao, S.; Wu, H.; Klein-Szanto, A.J.; Tahan, S.R. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol., 2007, 20(1), 102-107.
15. Monzani, E.; Facchetti, F.; Galmozzi, E.; Corsini, E.; Benetti, A.; Cavazzin, C.; Gritti, A.; Piccinini, A.; Porro, D.; Santinami, M.; Invernici, G.; Parati, E.; Alessandri, G.; La Porta, C.A. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer, 2007, 43(5), 935-946.
16. Quintana, E.; Shackleton, M.; Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumour formation by single human melanoma cells. Nature, 2008, 456(7222), 593-598.
17. Rappa, G.; Fodstad, O.; Lorico, A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells, 2008, 26(12), 3008-3017.
18. Topczewska, J.M.; Postovit, L.M.; Margaryan, N.V.; Sam, A.; Hess, A.R.; Wheaton, W.W.; Nickoloff, B.J.; Topczewski, J.; Hendrix, M.J. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med., 2006, 12(8), 925-932.
19. Strizzi, L.; Hardy, K.M.; Seftor, E.A.; Costa, F.F.; Kirschmann, D.A.; Seftor, R.E.B.; Postovit, L.-M.; Hendrix, M.J.C. Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res., 2009, 69(18), 7131-7134.
20. Chen, G.C.; Szakacs, G.; Annereau, J.P.; Rouzaud, F.; Liang, X.J.; Valencia, J.C.; Nagineni, C.N.; Hooks, J.J.; Hearing, V.J.; Gottesman, M.M., Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pig. Cell Res., 2005, 18(2), 102-112.
21. Rahmanto, S.Y.; Dunn, L.L.; Richardson, D.R. The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark-from iron metabolism to tumorigenesis. Carcinogenesis, 2007, 28(10), 2172-2183.
22. Keshet, G.I.; Goldstein, I.; Itzhaki, O.; Cesarkas, K.; Shenhav, L.; Yakirevitch, A.; Treves, A.J.; Schachter, J.; Amariglio, N.; Rechavi, G. MDR1 expression identifies human melanoma stem cells. Biochem. Biophys. Res. Commun., 2008, 368(4), 930-936.
23. Botelho, M.G.; Wang, X.; Arndt-Jovin, D.J.; Becker, D.; Jovin, T.M. Induction of Terminal Differentiation in Melanoma Cells on Downregulation of beta-Amyloid Precursor Protein. J. Invest. Dermatol., 2009, [Epub ahead of Print].
24. Hoek, K.S.; Eichhoff, O.M.; Schlegel, N.C.; Dobbeling, U.; Kobert, N.; Schaerer, L.; Hemmi, S.; Dummer, R. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res., 2008, 68(3), 650-656.
25. Hoek, K.S.; Eichhoff, O.M.; Widmer, D.; Dummer, R. Stemming the flood. Pig. Cell Melanoma Res., 2009, 22(1), 6-7.
26. Sousa, J.F.; Espreafico, E.M. Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer, 2008, 8, 19.
27. Elliott, A.M.; Al-Hajj, M.A. ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol. Cancer Res., 2009, 7(1), 79-87.
28. Huang, Y.; Anderle, P.; Bussey, K.J.; Barbacioru, C.; Shankavaram, U.; Dai, Z.; Reinhold, W.C.; Papp, A.; Weinstein, J.N.; Sadee, W. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res., 2004, 64(12), 4294-4301.
29. Folkman, J. Angiogenesis: an organizing principle for drug discovery?, Nat. Rev. Drug Discov., 2007, 6(4), 273-286. (Pubitemid 46505878)
30. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-364.
31. Soeda, A.; Park, M.; Lee, D.; Mintz, A.; Androutsellis-Theotokis, A.; McKay, R.D.; Engh, J.; Iwama, T.; Kunisada, T.; Kassam, A.B.; Pollack, I.F.; Park, D.M. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene, 2009, 28(45):3949-3959.
32. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I.T.; Zakharenko, S.S.; Gajjar, A.; Davidoff, A.; Gilbertson, R.J. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11(1), 69-82.
33. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A.B.; Shi, Q.; McLendon, R.E.; Bigner, D.D.; Rich, J.N. Stem celllike glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res., 2006, 66(16), 7843-7848.
34. Yao, X.-H.; Ping, Y.-F.; Chen, J.-H.; Xu, C.-P.; Chen, D.-L.; Zhang, R.; Wang, J.; Bian, X.-W. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J. Pathol., 2008, 215(4), 369-376.
35. Li, Z.; Bao, S.; Wu, Q.; Wang, H.; Eyler, C.; Sathornsumetee, S.; Shi, Q.; Cao, Y.; Lathia, J.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 2009, 15(6), 501-513.
36. Bertolini, F.; Shaked, Y.; Mancuso, P.; Kerbel, R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer, 2006, 6(11), 835-845.
37. Folkins, C.; Shaked, Y.; Man, S.; Tang, T.; Lee, C.R.; Zhu, Z.; Hoffman, R.M.; Kerbel, R.S. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res., 2009, 69(18), 7243-7251.
38. Maniotis, A.J.; Folberg, R.; Hess, A.; Seftor, E.A.; Gardner, L.M.; Pe'er, J.; Trent, J.M.; Meltzer, P.S.; Hendrix, M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol., 1999, 155(3), 739-752.
39. Naumov, G.N.; Bender, E.; Zurakowski, D.; Kang, S.Y.; Sampson, D.; Flynn, E.; Watnick, R.S.; Straume, O.; Akslen, L.A.; Folkman, J.; Almog, N. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl. Cancer Inst., 2006, 98(5), 316-325. (Pubitemid 43338211)
40. Folkins, C.; Man, S.; Xu, P.; Shaked, Y.; Hicklin, D.J.; Kerbel, R.S. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Cancer Res., 2007, 67(8), 3560-3564.
41. Schatton, T.; Frank, M.H. Antitumor immunity and cancer stem cells. Ann. NY Acad. Sci., 2009, 1176, 154-169.
42. Schatton, T.; Schütte, U.; Frank, N.Y.; Zhan, Q.; Hoerning, A.; Robles, S.C.; Zhou, J.; Hodi, F.S.; Spagnoli, G.C.; Murphy, G.F.; Frank, M.H. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res., 2010, 70(2), 697-708.
43. Rosenberg, S.A.; Restifo, N.P.; Yang, J.C.; Morgan, R.A.; Dudley, M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer, 2008, 8(4), 299-308.
44. Tarhini, A.A.; Kirkwood, J.M.; Gooding, W.E.; Cai, C.; Agarwala, S.S. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J. Clin. Oncol., 2007, 25(25), 3802-3807.
45. Fong, L.; Small, E.J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol., 2008, 26(32), 5275-5283.
46. Kirkwood, J.M.; Tarhini, A.A.; Panelli, M.C.; Moschos, S.J.; Zarour, H.M.; Butterfield, L.H.; Gogas, H.J. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J. Clin. Oncol., 2008, 26(20), 3445-3455.